– The Star –

– The Edge –

– The Star  –

PETALING JAYA: Medical consumables maker UMediC Group Bhd plans to nearly double its targeted production capacity of HydroX prefilled humidifiers, considering the robust demand for the product.

Post-meeting with the management, Hong Leong Investment Bank (HLIB) Research said UMediC’s newly guided plan is to increase the installed capacity of HydroX to 1.1 million bottles per month by the first quarter of 2025.

The previous target was 600,000 bottles per month by end-2024.

In fact, the 600,000 bottles target was already in addition to the 40% increase in installed capacity earlier in April this year, when the capacity rose from 300,000 bottles to 420,000 bottles per month.

HydroX prefilled humidifier is used to humidify the respiratory gas for patients and mostly used in oxygen therapy such as oxygen concentrators, gas cylinder or wall gas outlets via a mask or cannula in homecare, hospital, extended care facilities or hospital environment.

“Currently, UMediC is operating at 80% to 90% HydroX capacity, despite its recent 40% increase in capacity.

“Considering the robust demand, we believe that plant utilisation rate will be favourable to support its ambitious capacity expansion plan,” stated HLIB Research.

On UMediC’s marketing and distribution segment, HLIB Research expects meaningful order replenishment to happen in the first quarter of financial year 2025 (1Q25).

This is considering that the public tender for medical equipment has been slow as the Health Ministry (MoH) is finalising the structure to fully shift from an asset ownership model to a leasing model for medical equipment.

This could be part of the cost savings measures by the government.

“This sends three messages: First, we will not see a material rebound in orders in 4Q24 as MoH is still finalising the new procurement model. Nonetheless, we forecast a meaningful replenishment to happen in 1Q25.

“Second, upon finalisation, the revenue per equipment delivered will be lower – nevertheless, we believe this could potentially be offset by higher volume purchased (lower initial cash outlay for each equipment) coupled with winning over market share from its smaller peers, differentiated by its strong financial profile.

“Third, margin compression as a consequence of the government’s cost-savings measures. Nevertheless, we have imputed conservative pre-tax profit margins of 14.5% to 16% in the financial years of 2024 to 2026 (FY24 to FY26) post-results review.”

Looking ahead, HLIB Research has trimmed FY24 forecasts by 3% in response to unfavourable operating leverage effect following a soft recovery in the marketing and distribution segment in 4Q24.

“We maintain FY25 forecast but increase FY26 by 28% to primarily reflect the higher capacity expansion of HydroX to 1.1 million bottles per month by 1Q25,” it added.

HLIB Research has maintained its “buy” call on UMediC with a higher target price of RM1.02 per share.

“Our optimism towards UMediC remains intact, mainly fuelled by its robust capacity expansion in the manufacturing segment.”

– The Star  –

– Business Today  –

Revenue, however, rose to RM13.5mil against RM12.5mil posted a year earlier. Earnings per share for the period fell to 0.66 sen from 0.78 sen previously.

In the first six months to Jan 31, UMC posted a lower net profit of RM4.4mil from RM4.9mil, while revenue expanded RM28mil from RM23.8mil a year ago.

The company’s new plant began operations in March of this year. The medical-device maker has relocated its warehouse to the new facility to facilitate the expansion of its cleanroom facilities. The group’s monthly production capacity currently stands at about 420,000 bottles per month, a 40% increase from the previous 300,000. The production capacity is expected to reach 600,000, effectively doubling its previous capacity, by December of this year.

With the expansion in the capacity, UMC is venturing into the Latin American market to sell its products.

“We gather that the current workforce of 150 workers is sufficient to cater to the increased monthly production of up to 600,000 bottles through increased automation,” the research house noted.

The brokerage is reiterating its “buy” rating and target price at RM1.08, based on an unchanged 25 times price-earnings multiple on FY25 earnings per share.

– The Star  –